Abstract

Treatments like chemotherapy for cancer have less efficiency and specificity than required; immunotherapy provides one of the best means to have specific and more efficient treatment. With the great advancement in molecular biology, immunology, and cancer biology specific treatments like CAR-T immunotherapy have been introduced. Out of the various cancer immunotherapies discussed here, CAR-T immunotherapy provides the most promising results against certain cancers. CAR-T therapy has been discussed in detail with fundamental discussions of the immune system’s role in cancer and cancer immunotherapy. CAR-T immunotherapy a version of adoptive cell transfer therapy has given outstanding results that were beyond expectations. Some of them are discussed with minute details on CAR-T immunnnotherapy in this paper.
 

• 1.   Abate-Daga, D., & Davila, M. L. (2016). CAR models: next-generation CAR modifications forenhanced T-cellfunction. Molecular Therapy-Oncolytics, 3, 16014.
• 2.   Ahmad, A., Uddin, S., & Steinhoff,M.(2020). Cartcelltherapies: An overview of clinical studies
• 3.   Barrett, D.M., Teachey, D.T., & Grupp, S.A. (2014). Toxicitymanagementforpatientsreceiving novelTcellengagingtherapies.Current opinion in pediatrics, 26(1),43.
• 4.   Bell, J. C., Lichty, B., & Stojdl, D. (2003). Getting oncolyticvirus therapies off theground. Cancercell, 4(1), 7-11.
• 5.   Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., PérezGracia, J. L., ... & Melero, I. (2019). Cytokinesinclinicalcancerimmunotherapy.British journalofcancer,120(1),6-15.
• 6.   Borghaei, H., Smith, M. R., & Campbell, K. S. (2009). Immunotherapy of cancer. European journal
• 7.   Brentjens, R. J., & Curran, K. J. (2012). Novel cellular therapies for leukemia: CAR-modified Tcells targeted to the CD19 antigen. Hematology 2010, the American Society of Hematology
• 8.   Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010). Treatment of chroniclymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverseevent ina phaseIclinicaltrial.MolecularTherapy,18(4),666-668.
• 9.   Corthay, A. (2014). Does the immune system naturally protect against cancer?. Frontiers in
• 10.   Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., ... & Hall,
• 11.   Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018). Immune checkpoint inhibitors: recent progress and potential biomarkers.Experimental & molecular medicine, 50(12),1-11.
• 12.   Davenport, A. J., Jenkins, M. R., Cross, R. S., Yong, C. S., Prince, H. M., Ritchie, D. S., ... &Neeson,P.J.(2015).CAR-Tcellsinflictsequentialkillingofmultipletumortargetcells. Cancerimmunologyresearch,3(5),483-494.
• 13.   Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., ... & Brentjens, R. (2014).Efficacyandtoxicitymanagementof19-28zCARTcelltherapyinBcellacutelymphoblasticleukemia. Science translationalmedicine, 6(224),224ra25-224ra25.
• 14.   Dobosz, P., &Dzieciątkowski, T. (2019). Theintriguing history of cancer immunotherapy. Frontiers inimmunology,2965.
• 15.   Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance andimmunoediting. Immunity,21(2),137-148.
• 16.   Eggermont, L. J., Paulis, L. E., Tel, J., & Figdor, C. G. (2014). Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends in biotechnology, 32(9), 456-465
• 17.   Eshhar, Z., Bach, N., Fitzer-Attas, C. J., Grosse, G., Lustgarten, J., Waks, T., & Schindler, D. G.(1996,June).TheT-bodyapproach:potentialforcancerimmunotherapy.In Springerseminarsinimmunopathology(Vol.18,No.2,pp.199-209). Springer-Verlag.
• 18.   Fairweather,D.,&Cihakova,D.(2009).Alternativelyactivatedmacrophagesininfectionandautoimmunity.Journalofautoimmunity,33(3-4),222-230.
• 19.   Fan, J., Shang, D., Han, B., Song, J., Chen, H., & Yang, J. M. (2018). Adoptive cell transfer: is it apromisingimmunotherapyforcolorectalcancer?.Theranostics, 8(20),5784
• 20.   Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019). An introduction tochimericantigenreceptor(CAR)T cellimmunotherapyforhumancancer. Americanjournalofhematology,94(S1),S3-S9.
• 21.   Fukuhara,H.,Ino,Y.,& Todo, T. (2016).Oncolyticvirus therapy:A new era of cancertreatmentatdawn. Cancerscience,107(10),1373-1379.
• 22.   G.(1999).Anti-tumoractivityofhumanTcellsexpressingtheCC49-zetachimericimmunereceptor. Humangenetherapy,10(2),165-173.
• 23.   Gasteiger, G., & Rudensky, A. Y. (2014). Interactions between innate and adaptive lymphocytes. NatureReviewsImmunology,14(9),631-639.
• 24.   Giavridis, T., van derStegen, S. J.,Eyquem, J., Hamieh, M., Piersigilli,A.,& Sadelain,M.(2018). CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL1blockade. Nature medicine,24(6),731-738.
• 25.   Gonzalez, H., Hagerling, C., & Werb, Z. (2018). Roles of the immune system in cancer:
• 26.   Graham, C., Hewitson, R., Pagliuca, A., & Benjamin, R. (2018). Cancer immunotherapy withCAR-Tcells–beholdthe future.ClinicalMedicine,18(4),324.
• 27.   Gross, G., Waks, T., & Eshhar, Z. (1989). Expression of immunoglobulin-T-cell receptor
• 28.   Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., ... & June, C. H.(2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal ofMedicine, 368(16),1509-1518.
• 29.   Guo,C.,Manjili,M.H.,Subjeck, J.R.,Sarkar,D.,Fishe r,P.B.,&Wang,X. Y.(2013).Therapeuticcancervacci nes:past,present, andfuture.Advancesincancerresear
• 30.   H.(2012).Decade-longsafetyandfunctionofretrovir al-modifiedchimeric antigen receptor Tcells.Science translationalmedicine, 4(132),132ra53-132ra53.
• 31.   H a a n e n , J . B . , & R o b e r t , C . ( 2 0 1 5 ) . I m m u n e c h e c k p o i n t i n h i b i t o r s . I m m u n o -Oncology,42,55-66.
• 32.   Hadden,J.W.(2003).Immunodeficiencyandcancer:p rospectsforcorrection. International immunopharmac ology,3(8),1061-1071.
• 33.   Hansen, H. P. (2007). Hair loss induced by chemotherapy: An anthropological study of
• 34.   Hao, N. B., Lü, M. H., Fan, Y. H., Cao, Y. L., Zhang, Z. R., & Yang, S. M. (2012). Macrophages in tumor micro environments and the progress ion of tumors. Clinical and Developmental Immunology, 2012.
• 35.   Hinrichs, C. S., & Rosenberg, S. A. (2014). Exploiting the curative potential of adoptive T-cell therapy forcancer. Immunological reviews, 257(1),56-71.
• 36.   Irving, B. A., & Weiss, A. (1991). The cytoplasmic domain of the T cell receptor ζ chain is sufficient
• 37.   Jin, K. T., Chen, B., Liu, Y. Y., Lan, H., & Yan, J. P. (2021). Monoclonal antibodies and
• 38.   June, C.H. (2007). Principles of adoptive T cell cancer therapy. The Journal of clinical investigation, 117(5), 1204-1212.
• 39.   June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1),64-73.
• 40.   June, C. H., Maus, M. V., Plesa, G., Johnson, L. A., Zhao, Y., Levine, B. L., ... & Porter, D. L. (2014).Engineered Tcellsfor cancer therapy. Cancer Immunology, Immunotherapy, 63(9), 969-975.
• 41.   June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cellimmunotherapyforhumancancer.Science, 359(6382),1361-1365.
• 42.   Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011). Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine, 3(95), 95ra73-95ra73
• 43.   Kochenderfer,J.N.,Wilson,W.H.,Janik,J.E.,Dudley,M.E.,Stetler-Stevenson,M.,Feldman,
• 44.   Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., & Ramakrishna, S. (2013). Immune system:adouble-edgedswordincancer.Inflammation Research,62(9), 823-834.
• 45.   Langers, I., Renoux, V. M., Thiry, M., Delvenne, P., & Jacobs, N. (2012). Natural killer cells: role in local tumor growth and metastasis. Biologics: targets & therapy, 6,73.
• 46.   Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., ... & Mackall, C. L.(2014). Current concepts in the diagnosis andmanagement of cytokine release syndrome. Blood, The Journal of the American Society of Hematology, 124(2), 188-195.
• 47.   Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., ... & Brenner, M.K. (2011). Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma. Blood, The Journal of the American Society of Hematology, 118(23), 6050-6056.
• 48.   Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., & Locati, M. (2004). The chemokine systemindiverseforms of macrophageactivationand polarization.Trendsin immunology,25(12),677-686.
• 49.   Marcus, A., & Eshhar, Z. (2011). Allogeneic adoptive cell transfer therapy as a potent universal treatmentfor cancer.Oncotarget,2(7),525.
• 50.   McCarthy, E.F. (2006). Thetoxins of WilliamB.Coley and the treatment of boneandsoft-tissuesarcomas. The Iowaorthopaedic journal, 26,154.
• 51.   Mcguinness, R.P., Ge,Y., Patel, S.D., Kashmiri, S.V., Lee, H.S., Hand, P.H., ... & Mcarthur, J.
• 52.   Mitchison, N.A.(1955). Studies on the immunological response toforeign tumor transplants in the mouse:
• 53.   Mohanty, R., Chowdhury, C. R., Arega, S., Sen, P., Ganguly, P., & Ganguly, N. (2019). CAR Tcelltherapy:A new era for cancer treatment.Oncologyreports, 42 (6), 2183-2195.
• 54.   Morrow, G. R., & Dobkin, P. L. (1988). Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions. Clinical Psychology Review, 8(5), 517-556.
• 55.   Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., ... & Go, W.
• 56.   Oiseth, S. J., & Aziz, M. S. (2017). Cancer immunotherapy: a brief review of the history,
• 57.   Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature
• 58.   Park, J. H., & Brentjens, R. J. (2015). Are all chimeric antigen receptors created equal?. Journal ofClinicalO ncology:OfficialJournaloftheAmericanSocietyof Clinical Oncology,33(6),651-653.
• 59.   Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor–
• 60.   Porter, D.L.,Levine, B.L.,Kalos,M.,Bagg,A.,& June,C.H.(2011). Chimericantigenreceptor–
• 61.   Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B., & Bar-Sagi, D.(2016). IL35-producing B cells promote the development of pancreatic neoplasia. Cancer discovery, 6(3),247-255.
• 62.   Ramos, C. A., & Dotti, G. (2011). Chimeric antigen receptor (CAR)-engineered lymphocytes
• 63.   Rezvani,K.(2019).Adoptivecelltherapyusingengi neerednaturalkillercells. Bonemarrowtransplantati on,54(2),785-788.
• 64.   Ruella, M., & Kalos, M. (2014). Adoptive immunotherapy for cancer. Immunological reviews, 257(1), 14-38.
• 65.   Ruf,P.,&Lindhofer,H.(2001).Inductionofalong-lasti
• 66.   S. A., ... & Rosenberg, S. A. (2010). Eradication of B-lineage cells and regression of lymphoma in a
• 67.   Sadelain, M., Brentjens, R., & Rivière, I. (2013). The basic principles of chimeric antigen receptordesign. Cancerdiscovery,3(4),388-398.
• 68.   Schirrmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to
• 69.   Scholler,J.,Brady,T.L.,Binder-Scholl,G.,Hwang,W.T.,Plesa,G.,Hege,K.M.,...&June,C.
• 70.   Skorka, K., Ostapinska, K., Malesa, A., & Giannopoulos, K. (2020). The application of CARTcellsinhaematological malignancies.ArchivumImmunologiaeetTherapiaeExperimentalis,68(6),1-19.
• 71.   Smyth, M. J., & Teng, M. W. (2018). 2018 Nobel Prize in physiology or medicine. Clinical & translationalimmunology,7(10).
• 72.   Soltantoyeh, T., Akbari, B., Karimi, A., Mahmoodi Chalbatani, G., Ghahri-Saremi, N., Hadjati, J., ... &Mirzaei, H.R. (2021). Chimericantigenreceptor (CAR) Tcell therapy formetastaticmelanoma: challenges and road ahead. Cells, 10(6), 1450.
• 73.   Southam, C.M., Brunschwig, A., Levin, A.G., & Dizon, Q.S. (1966).
• 74.   ectofleukocytesontransplantabilityofhumancancer.Cancer, 19(11),1743-1753.
• 75.   Spear, T. T., Nagato, K., & Nishimura, M. I. (2016). Strategies to genetically engineer T cells for cancerimmunotherapy. CancerImmunology,Immunotherapy,65(6),631-649.
• 76.   Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
• 77.   Taylor, C. W., & Kirby, A. M. (2015). Cardiac sideeffects from breast cancer radiotherapy. Clinical Oncology, 27(11), 621-629.
• 78.   The role of lymph node cells in conferring immunity by adoptive transfer. The Journal of experimentalmedicine, 102(2),157-177.
• 79.   Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011). Natural innate and adaptiveimmunitytocancer.Annualreview ofimmunology,29, 235-271.
• 80.   Waldman,A.D.,Fritz,J.M.,&Lenardo,M.J.(2020).
• 81.   idetocancerimmunotherapy: from Tcell basic science to clinical practice. Nature Reviews Immunology, 20(11), 651-668.
• 82.   Weiner,L.M.,Murray,J.C.,&Shuptrine,C.W.(2012).An t ibo dy- base di mm u n oth era pyo fc an cer . Cell,148(6),1081-1084.
• 83.   Wilson,C.B.,Rowell,E.,&Sekimata,M.(2009).EpigeneticcontrolofT-helper-celldifferentiation.Nature reviewsimmunology,9(2),91-105.
• 84.   Zang, X. (2018). 2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpointblockade–Apersonal account.Genes&diseases, 5(4),302.

Data Sharing Statement

Funding